NCT06904248

Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

Evaluation of the Efficacy and Safety of Meloxicam Injection for Postoperative Analgesia in Abdominal Surgery Patients: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Clinical Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 224 (actual)
• Sponsor: Yangtze River Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the analgesic efficacy and safety of meloxicam injection in subjects with moderate-to-severe pain following abdominal surgery. The primary efficacy endpoint is the summed pain intensity difference over 24 hours ( SPID24)

Conditions

• Participants With Acute Moderate to Severe Pain Following Abdominal Surgery

Interventions

Type	Name	Description
DRUG	Meloxicam Injection	Intravenous meloxicam Injection, 30mg every 24 hours, for a total of 2 doses
DRUG	Sodium Chloride Injection	Intravenous Sodium Chloride Injection, 18mg every 24 hours, for a total of 2 doses

Timeline

• Start date: 2024-01-29
• Primary completion: 2024-11-20
• Completion: 2025-02-10
• First posted: 2025-04-01
• Last updated: 2025-04-01

Locations

18 sites across 1 country: China